-
ArticlePublication 2023Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control …
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the US. A cost-effectiveness analysis was conducted using a Markov model based on the pharmacist-prescribing intervention used in The Alberta Clinical Trial in Optimizing Hypertension (or RxACTION). Outcomes included cardiovascular (CV) events, end-stage kidney disease events, life years, quality-adjusted life years (QALYs), lifetime costs, and lifetime incremental cost-effectiveness ratio (ICER). Costs were based on reimbursement rates, published literature, national…
State-Transition | Mathematical Models | Cost-Effectiveness Analysis | Chronic Disease/Risk | Clinical Care | Health/Medicine | North America -
ArticlePublication 2016Cost-Effectiveness of Intensive Blood Pressure Management
This article aimed to evaluate the cost-effectiveness of intensive blood pressure management compared with standard …
This article aimed to evaluate the cost-effectiveness of intensive blood pressure management compared with standard management among 68-year-old high-risk adults with hypertension but not diabetes. A Markov cohort model was developed to estimate lifetime costs and quality-adjusted life-years (QALYs) discounted at 3% annually. The Systolic Blood Pressure Intervention Trial (SPRINT) was used to estimate treatment effects and adverse event rates. The authors used Centers for Disease Control and Prevention Life Tables to project age- and…
State-Transition | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2015Cost-Effectiveness of Hypertension Therapy According to 2014 Guidelines
Because many eligible adults with hypertension in the United States remain untreated, the authors of …
Because many eligible adults with hypertension in the United States remain untreated, the authors of this article projected the cost-effectiveness of treating hypertension in U.S. adults according to the 2014 guidelines. The Cardiovascular Disease Policy Model was used to simulate drug-treatment and monitoring costs, costs averted for the treatment of cardiovascular disease, and quality-adjusted life-years (QALYs) gained by treating previously untreated adults between the ages of 35 and 74 years from 2014 through 2024. Cost-effectiveness…
State-Transition | Health Outcomes | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2011Cost-Effectiveness of Blood Pressure Screening in Adolescents in the U.S.
This article compares the long-term effectiveness and cost-effectiveness of 3 approaches to managing elevated blood …
This article compares the long-term effectiveness and cost-effectiveness of 3 approaches to managing elevated blood pressure (BP) in adolescents in the United States. These approaches are (1) no intervention, (2) "screen-and-treat," and (3) population-wide strategies to lower the entire BP distribution. The authors obtained BP distributions from the National Health and Nutrition Examination Survey 1999-2004 and used childhood-to-adult longitudinal correlation analyses to simulate the tracking of BP. They then used the coronary heart disease policy…
State-Transition | Health Outcomes | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2005Cost-Effectiveness Analysis of Hypertension Guidelines in South Africa
This article aimed to investigate the cost-effectiveness of different strategies for initiation of drug treatment …
This article aimed to investigate the cost-effectiveness of different strategies for initiation of drug treatment (i.e., guideline-based on blood pressure level or based on absolute cardiovascular disease (CVD) risk) in developing countries. The authors used a Markov CVD model to compare the following 6 strategies: 2 different blood pressure levels (160/95 and 140/90 mm Hg) and 4 different levels of absolute CVD risk over 10 years (40%, 30%, 20%, and 15%)—with one of no treatment.…
State-Transition | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | Sub-Saharan Africa
5 Shown
General Resources
Teaching Resources
Collections
Format
Learner Level
Teaching Topic